Leishmaniasis is a vector-borne tropical disease caused by protozoan parasites of the genus Leishmania. The disease affects the skin, mucosal tissues, and visceral organs of humans and other mammals. Leishmaniasis treatment includes drugs such as miltefosine, amphotericin B, and paromomycin, which provide symptomatic relief and help heal infections. The global leishmaniasis treatment market is estimated to be valued at US$ 69.4 Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
A key trend driving the global leishmaniasis treatment market growth is the increasing incidences of leishmaniasis infections worldwide. According to the World Health Organization (WHO), leishmaniasis is endemic in 98 countries across the world. There are an estimated 0.2 to 0.4 million visceral leishmaniasis cases and 0.7 to 1.3 million cutaneous leishmaniasis cases reported annually worldwide. The rising burden of leishmaniasis infections is prompting healthcare agencies and drug makers to develop more effective treatment options. Several pharmaceutical companies are investing in R&D activities to develop novel drugs with higher efficacy and safety for treating various clinical manifestations of leishmaniasis. This focus on new product development and launches is expected to boost the leishmaniasis treatment market growth during the forecast period.
Segment Analysis
The global leishmaniasis treatment market is segmented by type of leishmaniasis into cutaneous leishmaniasis, mucocutaneous leishmaniasis, and visceral leishmaniasis. The visceral leishmaniasis segment accounts for the largest market share as it is the most severe form of the disease. It affects internal organs like liver and spleen and can be life threatening if left untreated.
Key Takeaways
The Global Leishmaniasis Treatment Market Size is expected to witness high growth over the forecast period owing to the rising prevalence of the vector-borne disease across tropical and subtropical regions globally.
Regional analysis: The leishmaniasis treatment market in Asia Pacific region is expected to grow at the fastest rate during the forecast period. Countries like India, Bangladesh and Nepal account for over 90% of the global visceral leishmaniasis cases. The high population living in poverty without access to proper healthcare facilities and stagnant water bodies providing breeding grounds to sandflies make these regions highly susceptible to the disease.
Key players operating in the leishmaniasis treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. The market is quite concentrated with few approved drugs and a majority share held by generic antimonial drugs. The key players are focusing on development of novel treatment options and initiatives to improve access in endemic regions.
For More Insights, Read: https://www.newswirestats.com/leishmaniasis-treatment-market-size-share-and-growth-forecast-2023-2030/
Related Reports: https://www.newsintv.com/health/crispr-and-cas-gene-a-revolutionary-gene-editing-technology/
Further, this report also highlights the regional and country-level market analysis.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the cutaneous leishmaniasis drugs market include Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Cutaneous Leishmaniasis Drugs Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/cutaneous-leishmaniasis-drugs-market/download-sampleMarket DynamicsThe devastating effect the non-life-threatening cutaneous leishmaniasis has on the local community is the main impetus for this market's growth.
The high spread of this disease among travelers and environmental changes like deforestation and agricultural practices will further enhance these drugs' market.
The disfiguring skin lesions leaving life-long scars leading to severe social stigma will increase the demand for these drugs, especially among women and children.
Increased government initiatives to curtail the spread of the diseases due to the dire consequences on the local community like ostracism, less education, and economic loss will benefit market growth.
